Curated News
By: NewsRamp Editorial Staff
July 29, 2025
Branded Legacy to Acquire Bio-Legacy, Pioneering Intranasal Drug Delivery Tech
TLDR
- Branded Legacy's acquisition of Bio-Legacy positions it to dominate the high-growth intranasal drug delivery market, offering a competitive edge in addiction treatments and vaccine accessibility.
- The $1.5 million Preferred D stock transaction transfers Bio-Legacy's equity, assets, and IP to Branded Legacy, with manufacturing prototyping set for Q3 2025 and market readiness by Q1 2027.
- This acquisition enhances global health by improving access to affordable naloxone devices, addressing addiction treatment challenges and contributing to a healthier tomorrow.
- Discover how Branded Legacy's strategic move into intranasal drug delivery could revolutionize addiction treatments with Bio-Legacy's patented naloxone device.
Impact - Why it Matters
This acquisition marks a pivotal moment in the health and wellness industry, particularly in addressing the critical challenges of addiction treatment and vaccine accessibility. The patented naloxone device by Bio-Legacy represents a significant advancement in drug delivery technologies, promising to make treatments more accessible and affordable. For investors and stakeholders, this move signals Branded Legacy's commitment to innovation and growth in high-demand markets. For the general public, it heralds the arrival of more effective solutions to pressing health challenges, potentially transforming lives and communities.
Summary
Branded Legacy (OTC: BLEG), a diversified holdings company with a focus on health and wellness solutions, has announced a significant move to acquire Bio-Legacy Evaluative Group, a leader in advanced intranasal drug delivery technologies. This acquisition, valued at $1.5 million in Preferred D stock, aims to transfer all of Bio-Legacy's equity, assets, and intellectual property to Branded Legacy. This strategic acquisition is set to propel Branded Legacy into the burgeoning markets of addiction treatments and vaccine accessibility, leveraging Bio-Legacy's patented naloxone device. This device is designed to tackle the challenges of cost and dosing in a market expected to surpass $1.16 billion by 2032. Post-acquisition, Bio-Legacy's CEO, Amin Janmohamed, will take on the roles of CEO and Chairman at Branded Legacy, with plans to begin manufacturing prototyping by Q3 2025 and to achieve market readiness for the naloxone device by Q1 2027.
For more details on this groundbreaking acquisition and its implications for the health and wellness sector, visit the full press release at https://ibn.fm/5kuAK. Branded Legacy continues to innovate in the biotech and wellness space, committed to enhancing lives and delivering sustainable value to its shareholders. Discover more about their vision and projects at https://BrandedLegacy.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Branded Legacy to Acquire Bio-Legacy, Pioneering Intranasal Drug Delivery Tech
